The stock of DiaMedica Therapeutics Inc (DMAC) has seen a 16.73% increase in the past week, with a 1.69% gain in the past month, and a 0.00% decrease in the past quarter. The volatility ratio for the week is 5.49%, and the volatility levels for the past 30 days are at 6.53% for DMAC. The simple moving average for the past 20 days is 17.30% for DMAC’s stock, with a 8.18% simple moving average for the past 200 days.
Is It Worth Investing in DiaMedica Therapeutics Inc (NASDAQ: DMAC) Right Now?
Moreover, the 36-month beta value for DMAC is 1.72. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DMAC is 23.78M and currently, short sellers hold a 0.74% of that float. On May 06, 2024, DMAC’s average trading volume was 37.33K shares.
DMAC) stock’s latest price update
DiaMedica Therapeutics Inc (NASDAQ: DMAC)’s stock price has soared by 14.07 in relation to previous closing price of 2.63. Nevertheless, the company has seen a gain of 16.73% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-18 that DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
Analysts’ Opinion of DMAC
Many brokerage firms have already submitted their reports for DMAC stocks, with Craig Hallum repeating the rating for DMAC by listing it as a “Buy.” The predicted price for DMAC in the upcoming period, according to Craig Hallum is $8 based on the research report published on April 24, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see DMAC reach a price target of $7. The rating they have provided for DMAC stocks is “Outperform” according to the report published on June 22nd, 2023.
Oppenheimer gave a rating of “Outperform” to DMAC, setting the target price at $27 in the report published on April 09th of the previous year.
DMAC Trading at 8.87% from the 50-Day Moving Average
After a stumble in the market that brought DMAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.84% of loss for the given period.
Volatility was left at 6.53%, however, over the last 30 days, the volatility rate increased by 5.49%, as shares surge +0.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.53% upper at present.
During the last 5 trading sessions, DMAC rose by +16.73%, which changed the moving average for the period of 200-days by -20.00% in comparison to the 20-day moving average, which settled at $2.56. In addition, DiaMedica Therapeutics Inc saw 5.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DMAC starting from Wambeke David J., who purchase 20,000 shares at the price of $2.46 back on Nov 16 ’23. After this action, Wambeke David J. now owns 527,114 shares of DiaMedica Therapeutics Inc, valued at $49,200 using the latest closing price.
Von Koch Thomas, the 10% Owner of DiaMedica Therapeutics Inc, purchase 1,470,588 shares at $3.40 during a trade that took place back on Jun 23 ’23, which means that Von Koch Thomas is holding 4,326,435 shares at $4,999,999 based on the most recent closing price.
Stock Fundamentals for DMAC
The total capital return value is set at -0.51. Equity return is now at value -46.77, with -43.77 for asset returns.
Based on DiaMedica Therapeutics Inc (DMAC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -46.24. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 4.59.
Currently, EBITDA for the company is -21.24 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.27.
Conclusion
To wrap up, the performance of DiaMedica Therapeutics Inc (DMAC) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
